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Background
On March 23, 2014, the World Health Organization (WHO) was notified of an out-
break of Ebola virus disease (EVD) in Guinea. On August 8, the WHO declared the 
epidemic to be a “public health emergency of international concern.”
Methods
By September 14, 2014, a total of 4507 probable and confirmed cases, including 
2296 deaths from EVD (Zaire species) had been reported from five countries in 
West Africa — Guinea, Liberia, Nigeria, Senegal, and Sierra Leone. We analyzed a 
detailed subset of data on 3343 confirmed and 667 probable Ebola cases collected 
in Guinea, Liberia, Nigeria, and Sierra Leone as of September 14.
Results
The majority of patients are 15 to 44 years of age (49.9% male), and we estimate that 
the case fatality rate is 70.8% (95% confidence interval [CI], 69 to 73) among per-
sons with known clinical outcome of infection. The course of infection, including 
signs and symptoms, incubation period (11.4 days), and serial interval (15.3 days), 
is similar to that reported in previous outbreaks of EVD. On the basis of the initial 
periods of exponential growth, the estimated basic reproduction numbers (R0) are 
1.71 (95% CI, 1.44 to 2.01) for Guinea, 1.83 (95% CI, 1.72 to 1.94) for Liberia, and 
2.02 (95% CI, 1.79 to 2.26) for Sierra Leone. The estimated current reproduction 
numbers (R) are 1.81 (95% CI, 1.60 to 2.03) for Guinea, 1.51 (95% CI, 1.41 to 1.60) 
for Liberia, and 1.38 (95% CI, 1.27 to 1.51) for Sierra Leone; the corresponding 
doubling times are 15.7 days (95% CI, 12.9 to 20.3) for Guinea, 23.6 days (95% CI, 
20.2 to 28.2) for Liberia, and 30.2 days (95% CI, 23.6 to 42.3) for Sierra Leone. As-
suming no change in the control measures for this epidemic, by November 2, 2014, 
the cumulative reported numbers of confirmed and probable cases are predicted to 
be 5740 in Guinea, 9890 in Liberia, and 5000 in Sierra Leone, exceeding 20,000 in 
total.
Conclusions
These data indicate that without drastic improvements in control measures, the 
numbers of cases of and deaths from EVD are expected to continue increasing from 
hundreds to thousands per week in the coming months.
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A s of September 14, 2014, a total of 4507 confirmed and probable cases of Ebola virus disease (EVD), as well as 2296 
deaths from the virus, had been reported from 
five countries in West Africa — Guinea, Liberia, 
Nigeria, Senegal, and Sierra Leone. In terms of 
reported morbidity and mortality, the current 
epidemic of EVD is far larger than all previous 
epidemics combined. The true numbers of cases 
and deaths are certainly higher. There are nu-
merous reports of symptomatic persons evading 
diagnosis and treatment, of laboratory diagnoses 
that have not been included in national databas-
es, and of persons with suspected EVD who were 
buried without a diagnosis having been made.1
The epidemic began in Guinea during De-
cember 2013,2 and the World Health Organiza-
tion (WHO) was officially notified of the rapidly 
evolving EVD outbreak on March 23, 2014. On 
August 8, the WHO declared the epidemic to be 
a “public health emergency of international con-
cern.”3 By mid-September, 9 months after the 
first case occurred, the numbers of reported 
cases and deaths were still growing from week 
to week despite multinational and multisectoral 
efforts to control the spread of infection.1 The 
epidemic has now become so large that the three 
most-affected countries — Guinea, Liberia, and 
Sierra Leone — face enormous challenges in im-
plementing control measures at the scale re-
quired to stop transmission and to provide clini-
cal care for all persons with EVD.
Because Ebola virus is spread mainly through 
contact with the body fluids of symptomatic 
patients, transmission can be stopped by a com-
bination of early diagnosis, contact tracing, pa-
tient isolation and care, infection control, and 
safe burial.1 Before the current epidemic in West 
Africa, outbreaks of EVD in central Africa had 
been limited in size and geographic spread, 
typically affecting one to a few hundred persons, 
mostly in remote forested areas.4 The largest 
previous outbreak occurred in the districts of 
Gulu, Masindi, and Mbarara in Uganda.5 This 
outbreak, which generated 425 cases over the 
course of 3 months from October 2000 to Janu-
ary 2001,6 was controlled by rigorous application 
of interventions to minimize further transmis-
sion — delivered through the local health care 
system, with support from international part-
ners.5,7,8
We now report on the clinical and epidemio-
logic characteristics of the epidemic in Guinea, 
Liberia, Nigeria, and Sierra Leone during the 
first 9 months of the epidemic (as of September, 
14, Senegal had reported only a single case). We 
document trends in the epidemic thus far and 
project expected case numbers for the coming 
weeks if control measures are not enhanced.
Me thods
Surveillance
Full details of the methods, along with sensitivity 
and uncertainty analyses, are provided in Supple-
mentary Appendix 1, available with the full text 
of this article at NEJM.org; a summary is pro-
vided here. Case definitions for EVD have been 
reported previously by the WHO.9 In brief, a sus-
pected case is illness in any person, alive or dead, 
who has (or had) sudden onset of high fever and 
had contact with a person with a suspected, 
probable, or confirmed Ebola case or with a dead 
or sick animal; any person with sudden onset of 
high fever and at least three of the following 
symptoms: headache, vomiting, anorexia or loss 
of appetite, diarrhea, lethargy, stomach pain, 
aching muscles or joints, difficulty swallowing, 
breathing difficulties, or hiccupping; or any per-
son who had unexplained bleeding or who died 
suddenly from an unexplained cause. A probable 
case is illness in any person suspected to have 
EVD who was evaluated by a clinician or any per-
son who died from suspected Ebola and had an 
epidemiologic link to a person with a confirmed 
case but was not tested and did not have labora-
tory confirmation of the disease. A probable or 
suspected case was classified as confirmed when 
a sample from the person was positive for Ebola 
virus in laboratory testing.  
Clinical and demographic data were collected 
with the use of a standard case investigation form 
(see Supplementary Appendix 1) on confirmed, 
probable, and suspected EVD cases identified 
through clinical care, including hospitalization, 
and through contact tracing in Guinea, Liberia, 
Nigeria, and Sierra Leone. To create the fullest 
possible picture of the unfolding epidemic, these 
data were supplemented by information collect-
ed in informal case reports, by data from diag-
nostic laboratories, and from burial records. The 
data recorded for each case included the district 
of residence, the district in which the disease 
was reported, the patient’s age, sex, and signs 
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and symptoms, the date of symptom onset and 
of case detection, the name of the hospital, the 
date of hospitalization, and the date of death or 
discharge. A subgroup of case patients provided 
information on potentially infectious contacts 
with other persons who had Ebola virus disease, 
including possible exposure at funerals. We 
present here the results from analyses of de-
tailed data on individual confirmed and proba-
ble cases recorded by each country in databases 
provided to the WHO as of September 14, 2014; 
analyses of confirmed and probable cases, to-
gether with suspected cases, are provided in 
Supplementary Appendix 1.
Ethical Considerations
This study is based on data collected during sur-
veillance and response activities for EVD in 
Guinea, Liberia, Nigeria, and Sierra Leone. All 
information on individual patients has been ano-
nymized for presentation.
Clinical Manifestations and Case Fatality Rate
We report on the frequency of symptoms in pa-
tients with confirmed and probable EVD cases 
overall and by country. We evaluated potential 
risk factors for a fatal outcome, including sex, 
age group (<15 years, 15 to 44 years, and ≥45 
years), general and hemorrhagic symptoms, and 
occupation (whether the patient was or was not a 
health care worker). We performed the analysis 
using logistic-regression models, with data on 
patients for whom there was a definitive outcome 
(death or recovery) by August 17, 2014.
The case fatality rate was calculated as the 
percentage of fatal EVD cases among reported 
cases with a known definitive clinical outcome 
(see Supplementary Appendix 1). For compari-
son, we also calculated a case fatality rate that was 
based only on the ratio of reported deaths to re-
ported cases, including in the denominator cases 
for which the clinical outcome is unknown.
Key Time Periods
We investigated five key time periods that char-
acterize the progression of infection, the detec-
tion, care, and recovery or death of a person with 
Ebola virus disease, and the transmission of in-
fection: the incubation period, which is the time 
between infection and the onset of symptoms 
(information that is relevant for assessing the 
length of time that case contacts have to be fol-
lowed up); the interval from symptom onset to 
hospitalization (which is indicative of the infec-
tious period in the community); the interval from 
hospital admission to death and the interval 
from hospital admission to discharge (both of 
which are relevant to assessing the demand for 
beds in relation to hospital capacity); the serial 
interval, which is defined as the interval between 
disease onset in an index case patient and dis-
ease onset in a person infected by that index case 
patient; and the generation time, which is the 
time between infection in an index case patient 
and infection in a patient infected by that index 
case patient (required to estimate the reproduc-
tion number, or R, of the epidemic).
The incubation period was estimated retro-
spectively (by having patients with confirmed 
cases recall the likely source of infection), with 
a distinction made between persons with single 
exposures and those with multiple exposures. In 
the case of multiple exposures, all the times of 
exposure were used to fit a parametric distribu-
tion (see Supplementary Appendix 1 for a sensi-
tivity analysis). The interval from symptom onset 
to hospitalization is summarized as the mean, 
rather than the median, number of days to re-
flect the average person-days of infectiousness 
in the community. The mean duration of hospi-
talization was estimated as the average number 
of days from hospitalization to discharge and 
the average number of days from hospitalization 
to death, weighted by the proportion of patients 
who died. For each statistic we calculated the 
mean, median, and interquartile range and fit-
ted a gamma probability distribution to model 
the variation among persons (see the results in 
Supplementary Appendix 1). Separate estimates 
were obtained for health care workers and for all 
other adults. The serial interval was estimated 
from a subgroup of patients for whom informa-
tion was available on the time of symptom onset 
in known or suspected chains of transmission. 
For EVD, we expect the generation time distribu-
tion to be nearly identical to the serial interval 
distribution (result derived in Supplementary 
Appendix 1).
Quantification of the Spread of Infection 
and Projection of Future Cases
The basic reproduction number (R0) is the aver-
age number of secondary cases that arise when 
one primary case is introduced into an uninfect-
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ed population. These secondary cases arise after 
a period measured by the serial interval or by the 
generation time. When R0 is greater than 1, in-
fection may spread in the population, and the 
rate of spread is higher with increasingly high 
values of R0. The doubling time (the time re-
quired for the incidence to double) was estimated 
on the basis of the reproduction number and the 
serial interval.11 After the early phase of expo-
nential growth in case numbers, once infection 
has become established, the number of people 
still at risk declines, so the reproduction number 
falls from its maximum value of R0 to a smaller, 
net reproduction number, Rt. When Rt falls below 
1, infection cannot be sustained. Estimates of R0 
and Rt help in evaluating the magnitude of the 
effort required to control the disease, the way in 
which transmission rates have fluctuated through 
time, and the effectiveness of control measures 
as they are implemented.
We estimated Rt over time from the time 
series of incidence of cases (i.e., a plot of the 
number of new cases per week over the course 
of the epidemic) and from our estimate of the 
serial interval distribution.12 We then estimated 
R0 for the early stages of the epidemic, when 
transmission rates were at their highest, on the 
basis of the date of symptom onset. As de-
scribed in Supplementary Appendix 1, average 
estimates of Rt for the period from July 28 to 
September 7, 2014, which were made on the 
basis of the date of report to facilitate com-
parison with future cases, were used to project 
future cases, allowing for both uncertainty in 
the estimates of Rt and stochastic variability in 
the transmission process.
R esult s
Scale of the Epidemic
A total of 4507 confirmed and probable EVD 
cases were reported to the WHO between De-
cember 30, 2013, and September 14, 2014 — a 
37-week period. A total of 718 confirmed and 
probable cases and 289 deaths were reported in 
the week of September 8 through September 14 
alone. The numbers of confirmed and probable 
cases reported by each country over time are 
shown in Figures 1 and 2. Detailed information 
was available on 3343 confirmed and 667 prob-
able cases; these cases were used in all our anal-
yses, with the exception of projections (results of 
analyses based on confirmed, probable, and sus-
pected cases are provided in Supplementary Ap-
pendix 1). The median age of persons with EVD 
was 32 years (interquartile range, 21 to 44), and 
there were no significant differences in the age 
distribution of persons with EVD among coun-
tries. The majority of persons with EVD (60.8%) 
were between 15 and 44 years of age (this age 
group makes up only 44% of the population) 
(Table 1). There were also no significant differ-
ences among countries in the total numbers of 
male and female persons with EVD reported 
(49.9% of the total were male patients; within-
country differences have not yet been fully inves-
tigated). EVD has taken a heavy toll among 
health care workers in Guinea, Liberia, and Si-
erra Leone. By September 14, a total of 318 cases, 
including 151 deaths, had been reported among 
health care workers.
Geographic Origin and the Spread  
of Infection
In December 2013, the first cases occurred in 
Guéckédou and Macenta districts, the focus of 
the epidemic in Guinea. During March 2014, a 
rise in the numbers of cases in these two dis-
tricts, in addition to the first reports from Lofa 
and other districts in Liberia, was followed by 
the discovery of cases in the capital, Conakry. A 
second increase in case incidence in Guinea — 
first in Guéckédou and Macenta and then in the 
capital — occurred in May and June.
During May, the focus of the epidemic in 
Guinea expanded to the neighboring districts of 
Kenema and Kailahun in Sierra Leone, and in 
June further cases were reported in Lofa district 
in Liberia. These five districts have remained the 
focus of transmission in the border areas of the 
three countries. From July onward, there were 
sharp increases in case numbers at the epidemic 
foci in all three countries, at other sites away 
from the epicenter, and in the capital cities of 
Conakry, Freetown, and Monrovia (Fig. 1, and 
animated map and timeline at NEJM.org). How-
ever, although EVD has spread to many parts of 
Guinea, Liberia, and Sierra Leone, it has not 
been reported in all districts in the countries: 
among the total of 67 districts in the three coun-
tries, only 43 have reported one or more con-
firmed, probable, or suspected cases, and more 
than 90% of cases have been reported from just 
14 districts.
An animated map 
with timeline is 
available at 
NEJM.org 
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Clinical Manifestations and Case Fatality Rate
Table 1 provides information on demographic 
characteristics and symptom frequency in pa-
tients with confirmed or probable EVD with a 
definitive outcome in Guinea, Liberia, Nigeria, 
and Sierra Leone. The most common symptoms 
reported between symptom onset and case detec-
tion included fever (87.1%), fatigue (76.4%), loss 
of appetite (64.5%), vomiting (67.6%), diarrhea 
(65.6%), headache (53.4%), and abdominal pain 
(44.3%). Specific hemorrhagic symptoms were 
rarely reported (in <1% to 5.7% of patients). “Un-
explained bleeding,” however, was reported in 
18.0% of cases. These patterns are similar in 
each country (see Supplementary Appendix 1).
Assessing the case fatality rate during this 
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Figure 1. Districts Affected by Ebola Virus Disease in Three Countries in Africa.
The map shows the districts that have been affected by Ebola virus disease in Guinea, Liberia, and Sierra Leone. 
Gray circles indicate the total numbers of confirmed and probable Ebola cases reported in each affected district, 
and red circles the number reported during the 21 days leading up to September 14, 2014.
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epidemic is complicated by incomplete informa-
tion on the clinical outcomes of many cases, 
both detected and undetected. Estimates of the 
case fatality rate (Table 2) derived by calculating 
the ratio of all reported deaths to all reported 
cases to date are low in comparison with his-
torical outbreaks and are highly variable among 
the affected countries. However, estimating the 
case fatality rate using only the 46% of cases 
with definitive recorded clinical outcomes gives 
higher estimates that show no significant varia-
tion among countries (Table 2). This analysis 
shows that by September 14, a total of 70.8% 
(95% confidence interval [CI], 68.6 to 72.8) of 
case patients with definitive outcomes have 
died, and this rate was consistent among Guin-
ea, Liberia, and Sierra Leone (Table 2). The case 
fatality rate in Nigeria was lower (45.5%), though 
this estimate is based on only 11 recent cases. 
The case fatality rate among hospitalized case 
N
o.
 o
f C
as
es
800
700
600
400
300
100
500
200
0
Jan
. 5
Jan
. 1
9
Fe
b. 
2
Fe
b. 
16
M
ar
ch
 2
M
ar
ch
 16
M
ar
ch
 30
Ap
ril
 13
Ap
ril
 27
M
ay
 11
M
ay
 25
Ju
ne
 8
Ju
ne
 22
Ju
ly 
6
Ju
ly 
20
Au
g. 
3
Au
g. 
17
Au
g. 
31
Se
pt
. 1
4
Jan
. 5
Jan
. 1
9
Fe
b. 
2
Fe
b. 
16
M
ar
ch
 2
M
ar
ch
 16
M
ar
ch
 30
Ap
ril
 13
Ap
ril
 27
M
ay
 11
M
ay
 25
Ju
ne
 8
Ju
ne
 22
Ju
ly 
6
Ju
ly 
20
Au
g. 
3
Au
g. 
17
Au
g. 
31
Se
pt
. 1
4
Jan
. 5
Jan
. 1
9
Fe
b. 
2
Fe
b. 
16
M
ar
ch
 2
M
ar
ch
 16
M
ar
ch
 30
Ap
ril
 13
Ap
ril
 27
M
ay
 11
M
ay
 25
Ju
ne
 8
Ju
ne
 22
Ju
ly 
6
Ju
ly 
20
Au
g. 
3
Au
g. 
17
Au
g. 
31
Se
pt
. 1
4
Jan
. 5
Jan
. 1
9
Fe
b. 
2
Fe
b. 
16
M
ar
ch
 2
M
ar
ch
 16
M
ar
ch
 30
Ap
ril
 13
Ap
ril
 27
M
ay
 11
M
ay
 25
Ju
ne
 8
Ju
ne
 22
Ju
ly 
6
Ju
ly 
20
Au
g. 
3
Au
g. 
17
Au
g. 
31
Se
pt
. 1
4
A West Africa
N
o.
 o
f C
as
es
400
300
100
200
0
B Guinea
N
o.
 o
f C
as
es
400
300
100
200
0
C Liberia
N
o.
 o
f C
as
es
400
300
100
200
0
D Sierra Leone
Guinea
Liberia
Nigeria
Sierra Leone
Confirmed case
Probable case
Suspected case
Confirmed case
Probable case
Suspected case
Confirmed case
Probable case
Suspected case
Figure 2. Weekly Incidence of Confirmed, Probable, and Suspected Ebola Virus Disease Cases.
Shown is the weekly incidence of confirmed, probable, and suspected EVD cases, according to actual or inferred week of symptom on-
set. A suspected case is illness in any person, alive or dead, who has (or had) sudden onset of high fever and had contact with a person 
with a suspected, probable, or confirmed Ebola case or with a dead or sick animal; any person with sudden onset of high fever and at 
least three of the following symptoms: headache, vomiting, anorexia or loss of appetite, diarrhea, lethargy, stomach pain, aching mus-
cles or joints, difficulty swallowing, breathing difficulties, or hiccupping; or any person who had unexplained bleeding or who died sud-
denly from an unexplained cause. A probable case is illness in any person suspected to have EVD who was evaluated by a clinician or 
any person who died from suspected Ebola and had an epidemiologic link to a person with a confirmed case but was not tested and did 
not have laboratory confirmation of the disease. A probable or suspected case was classified as confirmed when a sample from the per-
son was positive for Ebola virus in laboratory testing.
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patients was 64.3% (95% CI, 61.5 to 67.0) lower 
than that among all patients with definitive out-
comes and was consistent among countries. The 
case fatality rate among health care workers 
ranged from 56.1% (95% CI, 41.0 to 70.1) in 
Guinea to 80.0% (95% CI, 68.7 to 87.9) in Liberia 
(Table 2). Risk factors for a fatal outcome, after 
adjustment for country, are provided in Table 1. 
Significant risk factors for death include an age 
of 45 years or older as compared with 44 years 
of age or younger (odds ratio, 2.47; 95% CI, 1.79 
to 3.46) and a number of general symptoms 
(diarrhea, conjunctivitis, difficulty breathing or 
swallowing, confusion or disorientation, and 
coma) and hemorrhagic symptoms (unexplained 
bleeding, bleeding gums, bloody nose, bleeding 
at the injection site, and bleeding from the va-
gina) (odds ratios and 95% confidence intervals 
for these factors are provided in Table 1).
Key Time Periods
The mean incubation period was 11.4 days (Table 
2 and Fig. 3A), and did not vary by country (Fig. 
3B, 3C, and 3D). Approximately 95% of the case 
patients had symptom onset within 21 days after 
exposure (Fig. 3A), which is the recommended 
period for follow-up of contacts. The estimated 
mean (±SD) serial interval was 15.3±9.3 days 
(Table 2 and Fig. 3E), which is the same as the 
estimated mean generation time (see Supplemen-
tary Appendix 1). The mean time from the onset 
of symptoms to hospitalization, a measure of the 
period of infectiousness in the community, was 
5.0±4.7 days (Table 2), and was no shorter for 
health care workers than for other case patients. 
The mean time to death after admission to the 
hospital was 4.2±6.4 days, and the mean time to 
discharge was 11.8±6.1 days. The mean length of 
stay in hospital was 6.4 days in Guinea, Liberia, 
and Sierra Leone (Table 2).
Quantification of the Spread of Infection 
and Projection of Future Cases 
Estimates of the basic reproduction number, R0, 
were 1.71 (95% CI, 1.44 to 2.01) for Guinea, 1.83 
(95% CI, 1.72 to 1.94) for Liberia, 1.20 (95% CI, 
0.67 to 1.96) for Nigeria, and 2.02 (95% CI, 1.79 
to 2.26) for Sierra Leone (Table 2, and Fig. S7 in 
Supplementary Appendix 1). Although R0 reflects 
the maximum potential for growth in case inci-
dence, Figure S7 in Supplementary Appendix 1 
shows the variation in the estimated net repro-
duction number, Rt, during the course of the epi-
demic. Between March and July 2014, the Rt for 
Guinea fluctuated around the threshold value of 
1 but appeared to increase again in August, re-
flecting the rise in case incidence in Macenta dis-
trict. In Sierra Leone, the value of Rt dropped be-
tween June and August as the case incidence 
stabilized in Kenema and Kailahun. In Liberia, 
the Rt remained above 1 for most of the period 
between March and August, reflecting the con-
sistent increase in case incidence (Fig. S9) in that 
country.
The growing numbers of cases reported from 
Guinea, Liberia, and Sierra Leone in August and 
early September suggest that the Rt remains 
above 1 in a still-expanding epidemic (reliable 
estimates of Rt could be obtained only to early 
September owing to reporting delays). As of 
September 14, the doubling time of the epi-
demic was 15.7 days in Guinea, 23.6 days in Li-
beria, and 30.2 days in Sierra Leone (Table 2). 
We estimate that, at the current rate of increase, 
assuming no changes in control efforts, the cu-
mulative number of confirmed and probable 
cases by November 2 (the end of week 44 of the 
epidemic) will be 5740 in Guinea, 9890 in Libe-
ria, and 5000 in Sierra Leone, exceeding 20,000 
cases in total (Fig. 4, and Table S8 in Supple-
mentary Appendix 2). The true case load, includ-
ing suspected cases and undetected cases, will 
be higher still.
Discussion 
Although the current epidemic of EVD in West 
Africa is unprecedented in scale, the clinical 
course of infection and the transmissibility of 
the virus are similar to those in previous EVD 
outbreaks. The incubation period, duration of ill-
ness, case fatality rate, and R0 are all within the 
ranges reported for previous EVD epidem-
ics.7,13-18 Our estimates of R0 are similar to other 
recent estimates for this West Africa epidem-
ic.19-23 The combination of signs and symptoms 
recorded between symptom onset and clinical 
presentation is also similar to that in other re-
ports.14,17,24-26 We infer that the present epidemic 
is exceptionally large, not principally because of 
the biologic characteristics of the virus, but rath-
er because of the attributes of the affected popu-
lations and because control efforts have been 
insufficient to halt the spread of infection.
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Certain characteristics of the affected popula-
tions may have led to the rapid geographic dis-
semination of infection. The populations of 
Guinea, Liberia, and Sierra Leone are highly in-
terconnected, with much cross-border traffic at 
the epicenter and relatively easy connections by 
road between rural towns and villages and be-
tween densely populated national capitals. The 
large intermixing population has facilitated the 
spread of infection, but a large epidemic was 
not inevitable. In Nigeria, the number of cases 
has so far been limited, despite the introduction 
of infection into the large cities of Lagos (ap-
proximately 20 million people) and Port Har-
court (>1 million people). The critical determi-
nant of epidemic size appears to be the speed of 
implementation of rigorous control measures.
Previous experience with EVD outbreaks, 
though they have been limited in size and geo-
graphic spread, suggests that transmission can 
Table 1. Demographic Characteristics and Signs and Symptoms in Confirmed and Probable Ebola Case Patients with a 
Definitive Clinical Outcome in Guinea, Liberia, Nigeria, and Sierra Leone.*
Variable All Patients
Patients Who 
Died
Patients Who 
Recovered
Odds Ratio
(95% CI)†
no./total no. (%)
Demographic characteristics
Male sex 685/1415 (48.4) 515/1056 (48.8) 170/359 (47.4) 0.93 (0.73–1.19)
Age group
<15 yr 190/1378 (13.8) 145/1021 (14.2) 45/357 (12.6) 1.18 (0.83–1.71)
15–44 yr 838/1378 (60.8) 577/1021 (56.5) 261/357 (73.1) 0.48 (0.36–0.62) 
≥45 yr 350/1378 (25.4) 299/1021 (29.3) 51/357 (14.3) 2.47 (1.79–3.46)
Health care worker 158/1429 (11.1) 112/1067 (10.5) 46/362 (12.7) 0.86 (0.60–1.27)
Signs and symptoms
General symptoms
Fever‡ 1002/1151 (87.1) 746/846 (88.2) 256/305 (83.9) 1.34 (0.92–1.95)
Fatigue 866/1133 (76.4) 633/829 (76.4) 233/304 (76.6) 0.94 (0.68–1.28)
Loss of appetite 681/1055 (64.5) 498/778 (64.0) 183/277 (66.1) 0.92 (0.69–1.23)
Vomiting 753/1114 (67.6) 566/816 (69.4) 187/298 (62.8) 1.19 (0.89–1.59)
Diarrhea 721/1099 (65.6) 555/813 (68.3) 166/286 (58.0) 1.42 (1.06–1.89)
Headache 553/1035 (53.4) 407/757 (53.8) 146/278 (52.5) 1.03 (0.78–1.36)
Abdominal pain 439/992 (44.3) 311/715 (43.5) 128/277 (46.2) 0.85 (0.64–1.13)
Muscle pain 385/990 (38.9) 293/728 (40.2) 92/262 (35.1) 1.24 (0.92–1.67)
Joint pain 374/950 (39.4) 283/695 (40.7) 91/255 (35.7) 1.32 (0.98–1.80)
Chest pain 254/686 (37.0) 196/488 (40.2) 58/198 (29.3) 1.53 (1.07–2.20)
Cough 194/655 (29.6) 150/462 (32.5) 44/193 (22.8) 1.74 (1.18–2.61)
Difficulty breathing 155/665 (23.3) 123/472 (26.1) 32/193 (16.6) 1.68 (1.10–2.63)
Difficulty swallowing 169/514 (32.9) 138/375 (36.8) 31/139 (22.3) 2.22 (1.41–3.59)
Conjunctivitis 137/658 (20.8) 109/465 (23.4) 28/193 (14.5) 2.03 (1.29–3.29)
Sore throat 102/467 (21.8) 82/339 (24.2) 20/128 (15.6) 1.94 (1.13–3.46)
Confusion 84/631 (13.3) 68/446 (15.2) 16/185 (8.6) 2.00 (1.14–3.71)
Hiccups 108/947 (11.4) 91/699 (13.0) 17/248 (6.9) 2.15 (1.27–3.82)
Jaundice 65/627 (10.4) 52/443 (11.7) 13/184 (7.1) 1.83 (0.99–3.63)
Eye pain 48/622 (7.7) 39/438 (8.9) 9/184 (4.9) 1.95 (0.95–4.40)
Rash 37/642 (5.8) 30/453 (6.6) 7/189 (3.7) 1.90 (0.86–4.83)
Coma or unconsciousness 37/627 (5.9) 34/445 (7.6) 3/182 (1.6) 4.59 (1.61–19.34)
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be interrupted, and case incidence reduced, 
within 2 to 3 weeks after the introduction of 
control measures.1,5,7,14-17,24,27-31 This view is re-
inforced by the estimates of case reproduction 
number presented in this analysis. We estimate 
the R0 to have varied between 1.71 (upper bound-
ary of the 95% confidence interval, 2.01) in 
Guinea to 2.02 (upper boundary of the 95% 
confidence interval, 2.26) in Sierra Leone. This 
means that transmission has to be a little more 
than halved to achieve control of the epidemic 
and eventually to eliminate the virus from the 
human population. Considering the prospects 
for a novel Ebola vaccine, an immunization cov-
erage exceeding 50% would have the same ef-
fect. Greater reductions in transmission would, 
of course, be desirable, but minimum require-
ments for the containment of EVD are far less 
severe than for the containment of more conta-
gious diseases, such as measles. Between March 
and July 2014, the reproduction number in 
Guinea fluctuated around the threshold value of 
1, suggesting that modest further intervention 
efforts at that point could have achieved control.
The analyses in this paper can be used to 
inform recommendations regarding control 
measures. The measured duration of the incuba-
tion period, and its variation, imply that the 
advice to follow case contacts for 21 days1 is 
appropriate. To curtail transmission in the com-
munity, the period from symptom onset to hos-
pitalization (a mean of 5 days but a maximum of 
>40 days) clearly needs to be reduced. Surpris-
ingly, the mean was not shorter among health 
care workers, who are at risk both of acquiring 
and transmitting the infection to others. The 
average length of hospital stay of about 1 week 
(6.4 days) means that the number of beds re-
quired to treat EVD patients is roughly equal to 
the rising weekly case incidence. Even without 
allowing for underreporting, 995 patients with 
confirmed, probable, or suspected infection were 
known to need clinical care in the week of Sep-
tember 8 through 14 alone, which far exceeds 
the present bed capacity in Guinea, Liberia, and 
Sierra Leone (approximately 610 beds in total).
The data used in these analyses were collect-
ed in the field by various field teams across 
Guinea, Liberia, Nigeria, and Sierra Leone. Al-
though they provide an excellent opportunity to 
better understand the current EVD epidemic in 
Africa, they understate the magnitude of the 
Table 1. (Continued.)
Variable All Patients
Patients Who 
Died
Patients Who 
Recovered
Odds Ratio
(95% CI)†
no./total no. (%)
Unexplained bleeding 168/932 (18.0) 140/693 (20.2) 28/239 (11.7) 1.83 (1.20–2.90)
Hematemesis 26/670 (3.9) 20/503 (4.0) 6/167 (3.6) 1.07 (0.44–3.01)
Blood in stool 48/843 (5.7) 35/614 (5.7) 13/229 (5.7) 0.98 (0.52–1.96)
Bleeding gums 19/837 (2.3) 18/608 (3.0) 1/229 (0.4) 6.69 (1.35–121.32)
Bloody nose 16/836 (1.9) 15/610 (2.5) 1/226 (0.4) 8.02 (1.54–148.62)
Bloody cough 20/831 (2.4) 16/605 (2.6) 4/226 (1.8) 1.63 (0.58–5.82)
Other bleeding 8/657 (1.2) 5/493 (1.0) 3/164 (1.8) 0.45 (0.11–2.23)
Bleeding at injection site 20/833 (2.4) 19/605 (3.1) 1/228 (0.4) 6.51 (1.32–118.04)
Blood from vagina§ 14/431 (3.2) 13/290 (4.5) 1/126 (0.8) 6.0 (1.11–112.4)
Blood in urine 10/827 (1.2) 9/601 (1.5) 1/226 (0.4) 5.14 (0.90–98.73)
Bleeding under skin 5/827 (0.6) 5/604 (0.8) 0/223 NA
* Data are as of September 14, 2014. Patients with date of onset up to August 17, 2014, were included. Total numbers 
are the numbers of patients with data on the variable in question. NA denotes not applicable.
† Odds ratios are adjusted for country. CI denotes confidence interval.
‡ Fever was defined as a body temperature above 38°C; however, in practice, health care workers at the district level often 
do not have a medical thermometer and simply ask whether the person’s body temperature is more elevated than usual.
§ Percentages reflect only female patients.
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problem. It is likely that many cases have not 
been detected, and for those cases that have been 
reported, case records are often incomplete. 
Therefore, interpretation of the available case 
data requires care. We recognize, however, that 
data are being collected under extreme condi-
tions, and the top priorities are patient care, 
contact tracing, and limiting transmission in the 
community, rather than epidemiologic investiga-
tions. In addition, in this initial assessment it was 
not possible to consider all the sources of hetero-
geneity (e.g., geographic and health care-related) 
affecting the development of this epidemic. Thus 
the future projections provided here should be 
regarded as indicative of likely future trends more 
than precise predictions. Despite these limita-
tions and the resulting uncertainties, the results 
presented here help us to understand the spread 
of infection and the potential for control.
Some details of the current analysis remain 
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Figure 3. Time between Exposure and Disease Onset.
Panel A through D show the observed times (>0) between exposure and disease onset for all countries, Guinea,  
Liberia, and Sierra Leone, respectively, including only cases with multiple exposure days (histograms in gray), best-
fit (gamma) probability density function (red curves) and cumulative distribution for the incubation period (blue 
curves). Panel E shows the observed times between disease onset in an index case patient and disease onset in the 
person infected by the index case patient (histograms in gray) and best-fit (gamma) probability density function 
(red curve) and cumulative distribution (blue curve) for the serial interval.
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to be confirmed by further investigation. For 
example, our estimate of 15.3 days for the serial 
interval is slightly longer than past estimates.32,33
This may reflect the difficulties of collecting tem-
porally unbiased data on exposure through con-
tact tracing, either in the current outbreak or 
during previous outbreaks. Alternatively, a longer 
serial interval may indicate that case isolation has 
been less effective in the current epidemic, result-
ing in a higher proportion of transmission events 
occurring late in the course of illness.
Case fatality is among the most important 
topics for further investigation. Our estimates of 
case fatality are consistent in Guinea (70.7%), 
Liberia (72.3%), and Sierra Leone (69.0%) when 
estimates are derived with data only for patients 
with recorded definitive clinical outcomes (1737 
patients). Estimates for hospitalized patients 
with recorded definitive clinical outcomes are 
also consistent across countries but are lower 
than those for all patients with definitive clini-
cal outcomes. In contrast, simply taking the ra-
tio of reported deaths to reported cases gives 
estimates that differ among countries (Table 2). 
These discrepancies perhaps reflect the chal-
lenges of clinical follow-up and data capture. 
The lower case fatality rate among hospitalized 
patients than among all persons with EVD could 
indicate that hospitalization increased survival, 
that cases of EVD in nonhospitalized persons 
were more likely to be detected if they were fatal, 
or that some persons died before they could be 
admitted to the hospital. In each of the countries 
studied, the case fatality rate is lowest among per-
sons 15 to 44 year of age, and highest among 
persons 45 years of age or older, and some limited 
variation in the case fatality rate among health 
care workers was observed among countries. The 
reasons for this variation are not yet known. 
Moreover, the case fatality rate among hospital-
ized patients may differ from that among patients 
who are never seen by a physician. Liberia has 
reported an unusually high proportion of deaths 
among patients with suspected (but not probable 
or confirmed) EVD cases (58% [440 of 754 pa-
tients]), as compared with Guinea (13% [4 of 30 
patients]) and Sierra Leone (35% [74 of 213 pa-
tients]). The implication is that many true EVD 
case patients in Liberia may have died before re-
ceiving a definitive diagnosis.
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Figure 4. Observed and Projected Case Incidence.
Observed and projected weekly case incidence in Guinea (Panel A), Liberia (Panel B), and Sierra Leone (Panel C) are shown on linear 
(upper panels) and logarithmic (lower panels) scales
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